These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 36607480)
21. Therapeutic potential of curcumin in human prostate cancer. III. Curcumin inhibits proliferation, induces apoptosis, and inhibits angiogenesis of LNCaP prostate cancer cells in vivo. Dorai T; Cao YC; Dorai B; Buttyan R; Katz AE Prostate; 2001 Jun; 47(4):293-303. PubMed ID: 11398177 [TBL] [Abstract][Full Text] [Related]
22. Effect of curcumin on the interaction between androgen receptor and Wnt/β-catenin in LNCaP xenografts. Hong JH; Lee G; Choi HY Korean J Urol; 2015 Sep; 56(9):656-65. PubMed ID: 26366279 [TBL] [Abstract][Full Text] [Related]
23. Metformin represses androgen-dependent and androgen-independent prostate cancers by targeting androgen receptor. Wang Y; Liu G; Tong D; Parmar H; Hasenmayer D; Yuan W; Zhang D; Jiang J Prostate; 2015 Aug; 75(11):1187-96. PubMed ID: 25894097 [TBL] [Abstract][Full Text] [Related]
24. Curcumin interrupts the interaction between the androgen receptor and Wnt/β-catenin signaling pathway in LNCaP prostate cancer cells. Choi HY; Lim JE; Hong JH Prostate Cancer Prostatic Dis; 2010 Dec; 13(4):343-9. PubMed ID: 20680030 [TBL] [Abstract][Full Text] [Related]
25. Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models. Gravina GL; Marampon F; Giusti I; Carosa E; Di Sante S; Ricevuto E; Dolo V; Tombolini V; Jannini EA; Festuccia C Int J Oncol; 2012 Mar; 40(3):711-20. PubMed ID: 22134754 [TBL] [Abstract][Full Text] [Related]
26. An evaluation of the anti-neoplastic activity of curcumin in prostate cancer cell lines. Piantino CB; Salvadori FA; Ayres PP; Kato RB; Srougi V; Leite KR; Srougi M Int Braz J Urol; 2009; 35(3):354-60; discussion 361. PubMed ID: 19538771 [TBL] [Abstract][Full Text] [Related]
27. Benzyldihydroxyoctenone, a novel nonsteroidal antiandrogen, shows differential apoptotic induction in prostate cancer cells in response to their androgen responsiveness. Suh H; Oh HL; Lee CH J Microbiol Biotechnol; 2011 May; 21(5):540-4. PubMed ID: 21617354 [TBL] [Abstract][Full Text] [Related]
28. Curcumin loaded β-cyclodextrin-magnetic graphene oxide nanoparticles decorated with folic acid receptors as a new theranostic agent to improve prostate cancer treatment. Einafshar E; Javid H; Amiri H; Akbari-Zadeh H; Hashemy SI Carbohydr Polym; 2024 Sep; 340():122328. PubMed ID: 38857995 [TBL] [Abstract][Full Text] [Related]
29. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer. Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046 [TBL] [Abstract][Full Text] [Related]
30. Neuroprotective Effects of Curcumin-Loaded Emulsomes in a Laser Axotomy-Induced CNS Injury Model. Yilmaz EN; Bay S; Ozturk G; Ucisik MH Int J Nanomedicine; 2020; 15():9211-9229. PubMed ID: 33244233 [TBL] [Abstract][Full Text] [Related]
31. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells. Murthy S; Agoulnik IU; Weigel NL Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350 [TBL] [Abstract][Full Text] [Related]
32. Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line. Lazier CB; Thomas LN; Douglas RC; Vessey JP; Rittmaster RS Prostate; 2004 Feb; 58(2):130-44. PubMed ID: 14716738 [TBL] [Abstract][Full Text] [Related]
33. Fulvestrant (ICI 182,780) down-regulates androgen receptor expression and diminishes androgenic responses in LNCaP human prostate cancer cells. Bhattacharyya RS; Krishnan AV; Swami S; Feldman D Mol Cancer Ther; 2006 Jun; 5(6):1539-49. PubMed ID: 16818513 [TBL] [Abstract][Full Text] [Related]
34. Effects of a novel carbocyclic analog of pyrrolo[2,3-d]pyrimidine nucleoside on pleiotropic induction of cell death in prostate cancer cells with different androgen responsiveness. Suh H; Choi KW; Lee J; Ryou C; Rhee H; Lee CH Bioorg Med Chem Lett; 2016 Feb; 26(4):1130-5. PubMed ID: 26832220 [TBL] [Abstract][Full Text] [Related]
35. Difference in protein expression profile and chemotherapy drugs response of different progression stages of LNCaP sublines and other human prostate cancer cells. Lin HP; Lin CY; Hsiao PH; Wang HD; Jiang SS; Hsu JM; Jim WT; Chen M; Kung HJ; Chuu CP PLoS One; 2013; 8(12):e82625. PubMed ID: 24349321 [TBL] [Abstract][Full Text] [Related]
36. Therapeutic potential of curcumin in human prostate cancer. II. Curcumin inhibits tyrosine kinase activity of epidermal growth factor receptor and depletes the protein. Dorai T; Gehani N; Katz A Mol Urol; 2000; 4(1):1-6. PubMed ID: 10851300 [TBL] [Abstract][Full Text] [Related]
37. Androgen-independent LNCaP cells are a subline of LNCaP cells with a more aggressive phenotype and androgen suppresses their growth by inducing cell cycle arrest at the G1 phase. Yu P; Duan X; Cheng Y; Liu C; Chen Y; Liu W; Yin B; Wang X; Tao Z Int J Mol Med; 2017 Nov; 40(5):1426-1434. PubMed ID: 28901378 [TBL] [Abstract][Full Text] [Related]
38. NF-kappaB2/p52 enhances androgen-independent growth of human LNCaP cells via protection from apoptotic cell death and cell cycle arrest induced by androgen-deprivation. Nadiminty N; Chun JY; Lou W; Lin X; Gao AC Prostate; 2008 Dec; 68(16):1725-33. PubMed ID: 18781579 [TBL] [Abstract][Full Text] [Related]
39. Mechanism of Anti-Cancer Activity of Curcumin on Androgen-Dependent and Androgen-Independent Prostate Cancer. Abd Wahab NA; Lajis NH; Abas F; Othman I; Naidu R Nutrients; 2020 Mar; 12(3):. PubMed ID: 32131560 [TBL] [Abstract][Full Text] [Related]